Modular Medical (MODD) Q4 2024 earnings summary

Executive summary

• The company is a pre-revenue medical device firm focused on developing and commercializing a novel, simplified insulin pump (MODD1) targeting both type 1 and type 2 diabetes markets, aiming to expand pump adoption beyond highly motivated users.

• In January 2024, a 510(k) premarket notification for MODD1 was submitted to the FDA; comments were received in March 2024 and responses are in progress.

• The company completed public offerings in May 2023 and February 2024, raising net proceeds of $9.7M and $10.3M, respectively, but still faces substantial doubt about its ability to continue as a going concern without additional capital.

Financial highlights

• No revenue was generated for the years ended March 31, 2024 and 2023.

• Net loss for fiscal 2024 was $17.5M, compared to $13.9M in fiscal 2023, reflecting increased R&D and ongoing operating expenses.

• Cash and cash equivalents as of March 31, 2024 were $9.2M, with an accumulated deficit of $65.9M.

• R&D expenses rose 42% year-over-year to $12.9M, driven by increased personnel, consulting, and FDA submission costs.

• G&A expenses decreased 3.5% year-over-year to $4.6M, mainly due to lower stock-based compensation and consulting fees.

Outlook and guidance

• The company expects R&D and G&A expenses to increase in fiscal 2025 as it prepares for commercialization and continues to respond to FDA feedback.

• A soft launch is planned following FDA clearance, with a full commercial launch anticipated in early 2025.

• Additional capital will be required to fund operations and commercialization efforts; failure to secure funding may result in curtailment of development or operations.